// you’re reading...

General Biotechnology

Is ImClone Out of the Woods?

Is ImClone Out of the Woods?
If the FDA approves its Erbitux anticancer treatment, as S&P expects, the biotech’s volatile stock should be set for solid growth

Discussion

No comments for “Is ImClone Out of the Woods?”

Post a comment